Research and Development
GSK announces positive data from phase 3 trial for new UTI antibiotic
April 17, 2023 Research and Development
GSK has shared positive data from its phase 3 trial for gepotidacin as a new oral antibiotic for the treatment …
Diabeloop announces collaboration with Novo Nordisk for connected diabetes treatment
April 14, 2023 Research and Development
Automated insulin delivery company Diabeloop has announced its collaboration with global healthcare company Novo Nordisk, with an agreement which covers …
Merck’s relapsing multiple sclerosis trial put on FDA partial clinical hold over liver injuries
April 14, 2023 Research and Development
Merck has announced that its clinical phase 3 study EVOLUTION has been put on partial clinical hold by the FDA …
Biogen announces licensing of Denali’s ATV to target Amyloid Beta
April 13, 2023 Research and Development
Biogen and Denali Therapeutics have announced that Biogen has exercised its option to license Denali’s Antibody Transport Vehicle: Amyloid beta …
Aspect Biosystems and Novo Nordisk partner with $75m deal to develop bioprinted tissue therapeutics
April 13, 2023 Research and Development
Canadian biotech company Aspect Biosystems and Denmark-based Novo Nordisk have announced a collaboration, development and license agreement to develop bioprinted …
Moderna announces mixed success clinical updates for mRNA pipeline
April 12, 2023 Research and Development
Biotechnology company Moderna has announced clinical updates detailing the expansion and advancement of its mRNA pipeline, which includes treatments for …
Molecular Templates announces hold for phase 1 study
April 11, 2023 Research and Development
Molecular Templates has announced that the FDA has placed a partial hold on its phase 1 study for MT-0169 based …
Synapse receives FDA approval for its NeuRx DPS to treat patients with stable SCI
April 6, 2023 Research and Development
Synapse Biomedical has announced that it has gained premarket approval (PMA) from the FDA for its NeuRxDiaphragm Pacing System (NeuRx …
Vertex Pharmaceuticals and CRISPR Therapeutics submit FDA rolling Biologics License Applications for gene editing-based medicine
April 4, 2023 Research and Development
US-based Vertex Pharmaceuticals and Swiss CRISPR Therapeutics have announced the completion of their rolling Biologics License Applications (BLAs) to the …
aVaxziPen announces positive data for multiple diseases with novel needle-free vaccine
April 3, 2023 Research and Development
aVaxziPen, a biotech company focusing on the development of a novel needle-free vaccine delivery platform, has announced that it will …
Janssen reports new Rybrevant data for patients with advanced non-small cell lung cancer
March 30, 2023 Research and Development
Janssen, part of Johnson & Johnson, has announce new long-term data from its CHRYSALIS study, which assessed Rybrevant (amivantamab) in …
Netris Pharma doses first patient in pancreatic cancer study
March 29, 2023 Research and Development
Netris Pharma has announced that it has dosed its first patient in the Lap-NET1 study for the safety and efficacy …
AbbVie’s upadacitinib meets primary endpoint in trial for systemic lupus erythematosus
March 29, 2023 Research and Development
AbbVie has shared that upadacitinib (Rinvoq) has been shown to be effective in treating patients with moderately-to-severely-active systemic lupus erythematosus …
Novo Nordisk announces results from phase 3 PIONEER PLUS trial
March 28, 2023 Research and Development
Novo Nordisk has announced headline results from the phase 3b PIONEER PLUS trial for the safety and efficacy of once-daily …
GSK shares promising clinical trial results for endometrial cancer therapy
March 28, 2023 Research and Development
GSK has announced promising results from part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) alongside standard-of-care chemotherapy …
Latest content
Medtronic secures CE Mark for new cardiac pacing portfolio
October 30, 2026
Dermatology leader Doncker is new Onicor CEO
October 29, 2026
October 28, 2026
